uniQureQURE
About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Employees: 209
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
292% more call options, than puts
Call options by funds: $51.5M | Put options by funds: $13.2M
281% more capital invested
Capital invested by funds: $193M [Q3] → $734M (+$541M) [Q4]
33% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 27
5.53% more ownership
Funds ownership: 79.83% [Q3] → 85.36% (+5.53%) [Q4]
5% more funds holding
Funds holding: 130 [Q3] → 137 (+7) [Q4]
23% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 47
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
Chardan Capital Daniil Gataulin 16% 1-year accuracy 8 / 49 met price target | 192%upside $38 | Buy Maintained | 1 Apr 2025 |
HC Wainwright & Co. Patrick Trucchio 15% 1-year accuracy 28 / 186 met price target | 438%upside $70 | Buy Reiterated | 4 Mar 2025 |
Wells Fargo Yanan Zhu 12% 1-year accuracy 2 / 17 met price target | 131%upside $30 | Equal-Weight Maintained | 28 Feb 2025 |
RBC Capital Luca Issi 7% 1-year accuracy 4 / 55 met price target | 85%upside $24 | Outperform Reiterated | 21 Jan 2025 |
Financial journalist opinion









